Literature DB >> 23729174

Human and experimental evidence supporting a role for osteopontin in alcoholic hepatitis.

Oriol Morales-Ibanez1, Marlene Domínguez, Sung H Ki, Miguel Marcos, Javier F Chaves, Eric Nguyen-Khac, Hakim Houchi, Silvia Affò, Pau Sancho-Bru, José Altamirano, Javier Michelena, Juan Carlos García-Pagán, Juan G Abraldes, Vicente Arroyo, Juan Caballería, Francisco-Javier Laso, Bin Gao, Ramón Bataller.   

Abstract

UNLABELLED: We identified, in the transcriptome analysis of patients with alcoholic hepatitis (AH), osteopontin (OPN) as one of the most up-regulated genes. Here, we used a translational approach to investigate its pathogenic role. OPN hepatic gene expression was quantified in patients with AH and other liver diseases. OPN protein expression and processing were assessed by immmunohistochemistry, western blotting and enzyme-linked immunosorbent assay. OPN gene polymorphisms were evaluated in patients with alcoholic liver disease. The role of OPN was evaluated in OPN(-/-) mice with alcohol-induced liver injury. OPN biological actions were studied in human hepatic stellate cells (HSCs) and in precision-cut liver slices. Hepatic expression and serum levels of OPN were markedly increased in AH, compared to normal livers and other types of chronic liver diseases, and correlated with short-term survival. Serum levels of OPN also correlated with hepatic expression and disease severity. OPN was mainly expressed in areas with inflammation and fibrosis. Two proteases that process OPN (thrombin and matrix metalloproteinase 7) and cleaved OPN were increased in livers with AH. Patients with AH had a tendency of a lower frequency of the CC genotype of the +1239C single-nucleotide polymorphism of the OPN gene, compared to patients with alcohol abuse without liver disease. Importantly, OPN(-/-) mice were protected against alcohol-induced liver injury and showed decreased expression of inflammatory cytokines. Finally, OPN was induced by lipopolysaccharide and stimulated inflammatory actions in HSCs.
CONCLUSION: Human and experimental data suggest a role for OPN in the pathogenesis of AH. Further studies should evaluate OPN as a potential therapeutic target.
© 2013 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23729174      PMCID: PMC3877722          DOI: 10.1002/hep.26521

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  29 in total

1.  Intrahepatic gene expression in human alcoholic hepatitis.

Authors:  Devanshi Seth; Mark D Gorrell; Shaun Cordoba; Geoffrey W McCaughan; Paul S Haber
Journal:  J Hepatol       Date:  2006-06-05       Impact factor: 25.083

2.  The impact of osteopontin promoter polymorphisms on the risk of calcium urolithiasis.

Authors:  Chia-Chu Liu; Shu-Pin Huang; Li-Yu Tsai; Wen-Jeng Wu; Suh-Hang Hank Juo; Yii-Her Chou; Chun-Hsiung Huang; Ming-Tsang Wu
Journal:  Clin Chim Acta       Date:  2010-02-06       Impact factor: 3.786

Review 3.  Alcoholic liver disease: pathogenesis and new targets for therapy.

Authors:  José Altamirano; Ramón Bataller
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-08-09       Impact factor: 46.802

Review 4.  Signalling pathways in alcohol-induced liver inflammation.

Authors:  Pranoti Mandrekar; Gyongyi Szabo
Journal:  J Hepatol       Date:  2009-03-28       Impact factor: 25.083

Review 5.  Control of osteopontin signaling and function by post-translational phosphorylation and protein folding.

Authors:  Christian C Kazanecki; Dana J Uzwiak; David T Denhardt
Journal:  J Cell Biochem       Date:  2007-11-01       Impact factor: 4.429

6.  A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis.

Authors:  Nicholas C Boetticher; Craig J Peine; Paul Kwo; Gary A Abrams; Tushar Patel; Bashar Aqel; Lisa Boardman; Gregory J Gores; William S Harmsen; Craig J McClain; Patrick S Kamath; Vijay H Shah
Journal:  Gastroenterology       Date:  2008-09-13       Impact factor: 22.682

7.  Hepatic expression of CXC chemokines predicts portal hypertension and survival in patients with alcoholic hepatitis.

Authors:  Marlene Dominguez; Rosa Miquel; Jordi Colmenero; Montserrat Moreno; Joan-Carles García-Pagán; Jaime Bosch; Vicente Arroyo; Pere Ginès; Juan Caballería; Ramón Bataller
Journal:  Gastroenterology       Date:  2009-01-31       Impact factor: 22.682

8.  A new scoring system for prognostic stratification of patients with alcoholic hepatitis.

Authors:  Marlene Dominguez; Diego Rincón; Juan G Abraldes; Rosa Miquel; Jordi Colmenero; Pablo Bellot; Joan-Carles García-Pagán; Rosamelia Fernández; Montserrat Moreno; Rafael Bañares; Vicente Arroyo; Joan Caballería; Pere Ginès; Ramón Bataller
Journal:  Am J Gastroenterol       Date:  2008-08-21       Impact factor: 10.864

9.  Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis.

Authors:  Wing-Kin Syn; Steve S Choi; Evaggelia Liaskou; Gamze F Karaca; Kolade M Agboola; Ye Htun Oo; Zhiyong Mi; Thiago A Pereira; Marzena Zdanowicz; Padmini Malladi; Yuping Chen; Cynthia Moylan; Youngmi Jung; Syamal D Bhattacharya; Vanessa Teaberry; Alessia Omenetti; Manal F Abdelmalek; Cynthia D Guy; David H Adams; Paul C Kuo; Gregory A Michelotti; Peter F Whitington; Anna Mae Diehl
Journal:  Hepatology       Date:  2010-10-21       Impact factor: 17.425

10.  The osteopontin level in liver, adipose tissue and serum is correlated with fibrosis in patients with alcoholic liver disease.

Authors:  Stéphanie Patouraux; Stéphanie Bonnafous; Cosmin S Voican; Rodolphe Anty; Marie-Christine Saint-Paul; Maria-Alessandra Rosenthal-Allieri; Hélène Agostini; Micheline Njike; Nadége Barri-Ova; Sylvie Naveau; Yannick Le Marchand-Brustel; Pascal Veillon; Paul Calès; Gabriel Perlemuter; Albert Tran; Philippe Gual
Journal:  PLoS One       Date:  2012-04-18       Impact factor: 3.240

View more
  49 in total

1.  Invariant natural killer T cells contribute to chronic-plus-binge ethanol-mediated liver injury by promoting hepatic neutrophil infiltration.

Authors:  Stephanie Mathews; Dechun Feng; Igor Maricic; Cynthia Ju; Vipin Kumar; Bin Gao
Journal:  Cell Mol Immunol       Date:  2015-02-09       Impact factor: 11.530

2.  Pentraxin-3 modulates lipopolysaccharide-induced inflammatory response and attenuates liver injury.

Authors:  Luis Perea; Mar Coll; Lucia Sanjurjo; Delia Blaya; Adil El Taghdouini; Daniel Rodrigo-Torres; José Altamirano; Isabel Graupera; Beatriz Aguilar-Bravo; Marta Llopis; Julia Vallverdú; Joan Caballeria; Leo A van Grunsven; Maria-Rosa Sarrias; Pere Ginès; Pau Sancho-Bru
Journal:  Hepatology       Date:  2017-07-18       Impact factor: 17.425

3.  Biomarkers of Macrophage Activation and Immune Danger Signals Predict Clinical Outcomes in Alcoholic Hepatitis.

Authors:  Banishree Saha; David Tornai; Karen Kodys; Adeyinka Adejumo; Patrick Lowe; Craig McClain; Mack Mitchell; Arthur McCullough; Srinivasan Dasarathy; Aimee Kroll-Desrosiers; Bruce Barton; Svetlana Radaeva; Gyongyi Szabo
Journal:  Hepatology       Date:  2019-05-27       Impact factor: 17.425

Review 4.  A Unifying Hypothesis Linking Hepatic Adaptations for Ethanol Metabolism to the Proinflammatory and Profibrotic Events of Alcoholic Liver Disease.

Authors:  Zhi Zhong; John J Lemasters
Journal:  Alcohol Clin Exp Res       Date:  2018-09-17       Impact factor: 3.455

Review 5.  Alcoholic liver disease: mechanisms of injury and targeted treatment.

Authors:  Alexandre Louvet; Philippe Mathurin
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-03-17       Impact factor: 46.802

6.  CCL20 mediates lipopolysaccharide induced liver injury and is a potential driver of inflammation and fibrosis in alcoholic hepatitis.

Authors:  Silvia Affò; Oriol Morales-Ibanez; Daniel Rodrigo-Torres; José Altamirano; Delia Blaya; Dianne H Dapito; Cristina Millán; Mar Coll; Jorge M Caviglia; Vicente Arroyo; Juan Caballería; Robert F Schwabe; Pere Ginès; Ramón Bataller; Pau Sancho-Bru
Journal:  Gut       Date:  2014-01-10       Impact factor: 23.059

7.  Osteopontin binding to lipopolysaccharide lowers tumor necrosis factor-α and prevents early alcohol-induced liver injury in mice.

Authors:  Xiaodong Ge; Tung-Ming Leung; Elena Arriazu; Yongke Lu; Raquel Urtasun; Brian Christensen; Maria Isabel Fiel; Satoshi Mochida; Esben S Sørensen; Natalia Nieto
Journal:  Hepatology       Date:  2014-03-01       Impact factor: 17.425

8.  Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis.

Authors:  Javier Michelena; José Altamirano; Juan G Abraldes; Silvia Affò; Oriol Morales-Ibanez; Pau Sancho-Bru; Marlene Dominguez; Juan Carlos García-Pagán; Javier Fernández; Vicente Arroyo; Pere Ginès; Alexandre Louvet; Philippe Mathurin; Wajahat Z Mehal; Juan Caballería; Ramón Bataller
Journal:  Hepatology       Date:  2015-04-13       Impact factor: 17.425

9.  Osteopontin Attenuates Secondary Neurodegeneration in the Thalamus after Experimental Stroke.

Authors:  Anne Ladwig; Rebecca Rogall; Jörg Hucklenbroich; Antje Willuweit; Michael Schoeneck; Karl-Josef Langen; Gereon R Fink; M Adele Rueger; Michael Schroeter
Journal:  J Neuroimmune Pharmacol       Date:  2018-11-28       Impact factor: 4.147

Review 10.  New treatment options for alcoholic hepatitis.

Authors:  Saggere Muralikrishna Shasthry; Shiv Kumar Sarin
Journal:  World J Gastroenterol       Date:  2016-04-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.